A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

Sponsor

Faron Pharmaceuticals Ltd (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05428969

Collaborator

(none)

181

Enrollment

Locations

Arms

Anticipated Duration (Months)

45.3

Patients Per Site

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.

Condition or Disease	Intervention/Treatment	Phase
Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Myelodysplastic Syndromes Relapsed/Refractory AML	Drug: Bexmarilimab Drug: Azacitidine Drug: Venetoclax	Phase 1/Phase 2

Detailed Description

This is a multicenter Phase 1/2 open-label, study to assess the safety, tolerability and preliminary efficacy of increasing doses of bexmarilimab (FP-1305) in patients with intermediate, high or very high-risk MDS, CMML with 10-19 % marrow blasts, CMML/MDS with failure to hypomethylating agent (HMA), or in patients with newly diagnosed AML non-fit for induction therapy or relapsed/refractory AML. The Phase 1 part of the study will identify a safe and tolerable bexmarilimab dose amongst four predefined dose levels using a bayesian optimal interval (BOIN) dose escalation design to identify the maximum tolerated dose (MTD) of bexmarilimab when administered in combination with SoC.

The Phase 2 of the study is an expansion phase to further evaluate the safety and preliminary efficacy of bexmarilimab treatment at RP2D combined with SoC and will follow a Simon's 2-stage design for each of the indications selected to continue forward from Phase 1. This design allows for the investigation of bexmarilimab activity and preliminary response assessments tailored to each indication and allows early stopping in case of futility using a minimum number of patients. Patients from Phase 1, with the selected indication to be investigated in Phase 2, that have been treated at RP2D may be counted towards the number of patients for Phase 2.

Both study phases consist of a screening period, a treatment period, an end of treatment (EoT) as safety follow-up and disease progression/survival follow-up.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

181 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination With Azacitidine or Azacitidine/Venetoclax in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Actual Study Start Date :

Jun 2, 2022

Anticipated Primary Completion Date :

Dec 31, 2023

Anticipated Study Completion Date :

Dec 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Phase 1 - Intermediate/high risk MDS, CMML 10-19%, MDS/CMML failure to HMA, r/r AML Standard of care azacitidine as per label; bexmarilimab 4 dose levels at once every week (Q1W) followed by once every 2 weeks (Q2W); 28-day cycle	Drug: Bexmarilimab Intravenous Other Names: FP-1305 Drug: Azacitidine As per label, subcutaneous
Experimental: Phase 1 - Newly diagnosed AML patients non-fit for induction therapy Standard of care azacitidine and venetoclax as per label; bexmarilimab 4 dose levels Q1W followed by Q2W; 28-day cycle	Drug: Bexmarilimab Intravenous Other Names: FP-1305 Drug: Azacitidine As per label, subcutaneous Drug: Venetoclax Oral Other Names: Venclyxto®
Experimental: Phase 2 - Intermediate/high risk MDS, CMML, MDS/CMML failure to HMA, r/r AML & newly diagnosed AML Standard of care venetoclax and/or azacitidine as per label plus bexmarilmab	Drug: Bexmarilimab Intravenous Other Names: FP-1305 Drug: Azacitidine As per label, subcutaneous Drug: Venetoclax Oral Other Names: Venclyxto®

Arm

Intervention/Treatment

Experimental: Phase 1 - Intermediate/high risk MDS, CMML 10-19%, MDS/CMML failure to HMA, r/r AML

Standard of care azacitidine as per label; bexmarilimab 4 dose levels at once every week (Q1W) followed by once every 2 weeks (Q2W); 28-day cycle

Drug: Bexmarilimab

Intravenous

Other Names:

FP-1305

Drug: Azacitidine

As per label, subcutaneous

Experimental: Phase 1 - Newly diagnosed AML patients non-fit for induction therapy

Standard of care azacitidine and venetoclax as per label; bexmarilimab 4 dose levels Q1W followed by Q2W; 28-day cycle

Drug: Bexmarilimab

Intravenous

Other Names:

FP-1305

Drug: Azacitidine

As per label, subcutaneous

Drug: Venetoclax

Oral

Other Names:

Venclyxto®

Experimental: Phase 2 - Intermediate/high risk MDS, CMML, MDS/CMML failure to HMA, r/r AML & newly diagnosed AML

Standard of care venetoclax and/or azacitidine as per label plus bexmarilmab

Drug: Bexmarilimab

Intravenous

Other Names:

FP-1305

Drug: Azacitidine

As per label, subcutaneous

Drug: Venetoclax

Oral

Other Names:

Venclyxto®

Outcome Measures

Primary Outcome Measures

Reporting of incidence and frequency of dose limiting toxicities (DLTs). [From study start to end of Cycle 1 (each cycle is 28 days)]
Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and serious adverse events (SAE). [From study start to 30 days after end of treatment (EOT)]
Complete response (CR) rate for MDS and CMML-2. [From study start to 30 days after EOT]
Overall response rate (ORR) for MDS and CMML failure to prior HMA. [From study start to 30 days after EOT]
Complete remission with incomplete blood recovery (CRi) for r/r AML. [From study start to 30 days after EOT]
Minimal residual disease (MRD) status for newly diagnosed AML. [From study start to 30 days after EOT]

Secondary Outcome Measures

Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and SAEs. [From study start to 30 days after EOT]
Clinical efficacy measures based on progression free survival analyses defined as the time from study start to the date of documented disease progression or death from any cause, whichever occurs first, up to 2 years. [24 months from study start]
Clinical efficacy measures based on overall survival analyses defined as the length measured from study start to death from any cause up to 2 years. [24 months from study start]
Anti-bexmarilimab antibody positivity occurrence rate pre-dose and at defined timepoints during treatment. [24 months from study start]
Serum concentrations of bexmarilimab at defined timepoints pre-dose and post-dose of single and repeat bexmarilimab administrations using peripheral blood. [From study start to end of Cycle 2 (each cycle is 28 days)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient ≥ 18 years of age who presents with one of the following conditions:
Morphologically confirmed diagnosis of MDS with revised International Prognostic Scoring System (rIPSS) risk categories: intermediate, high and very high.
Morphologically confirmed diagnosis of CMML-2 with indication for azacitidine treatment.
CMML and MDS patient with response failure to HMA or therapy regimen including HMA.
Morphologically confirmed diagnosis of r/r AML following at least 1 line of prior therapies with indication for azacitidine treatment.
Morphologically confirmed diagnosis of AML in patients unfit for induction therapy with indication for azacitidine-venetoclax treatment.
Leukocyte count < 20 x10^{9/L (< 25 x10}9/L for newly diagnosed AML). Hydroxycarbamide use is permitted to meet this criterion in MDS and AML but not in CMML.
Adequate renal function.
Adequate liver function.

Exclusion Criteria:

Patient with acute promyelocytic leukemia (APL) or myeloproliferative CMML as defined by leukocyte count > 13 x10^9/L.
Eastern Cooperative Oncology Group (ECOG) performance status >2 (except newly diagnosed AML where ECOG 3 is allowed for patients < 75 years).
Allogeneic transplantation less than 6 months prior screening.
Patient with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia).
The patient requires systemic corticosteroid (≥10 mg/day prednisone or equivalent) or other immunosuppressive treatment.
Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than 14 days or five half-lives (whichever is shorter) from a small molecule targeted therapy or oral anticancer chemotherapy before the first study treatment.
Any immunotherapy or investigational therapy within preceding 28 days from the first study treatment.
Pregnant or lactating women.
History of chronic ulcers or clinically relevant liver disease leading to Child Pugh Score C or higher.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Helsinki University Hospital	Helsinki	Finland	00029
2	Kuopio University Hospital	Kuopio	Finland	70210
3	Oulu University Hospital	Oulu	Finland	90029
4	Tampere University Hospital	Tampere	Finland	33520